United-Guardian (UG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on May 13, 2026, with voting conducted by proxy only; no in-person attendance or voting is permitted.
Stockholders will vote on electing seven directors, advisory votes on executive compensation and its frequency, and ratification of the independent auditor.
Proxy materials, including the Proxy Statement and Annual Report, are available online, and all proxies must be received before the meeting.
Voting matters and shareholder proposals
Proposals include electing seven directors, advisory votes on executive compensation and its frequency, and ratification of Grassi & Co. as independent auditor for 2026.
Advisory vote on executive compensation frequency offers options of one, two, or three years, with the Board recommending annual votes.
Stockholder proposals for the 2027 meeting must be submitted by December 14, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
The Board consists of seven directors, six of whom are independent under NASDAQ rules; Donna Vigilante is not independent due to her executive role.
The Board has Audit, Compensation, and Investment Committees, all composed of independent directors.
The Board does not have a lead director; independent directors meet in executive session at least twice per year.
Director nominations are handled by the full Board, with final selections by a majority of independent directors.
Latest events from United-Guardian
- Q1 2026 sales and net income surged on strong product demand and settlement income.UG
Q1 20268 May 2026 - Net sales and income fell, but pharmaceuticals and medical lubricants posted year-over-year growth.UG
Q4 202527 Mar 2026 - Annual meeting to elect directors, approve executive pay, and ratify auditor, with strong governance.UG
Proxy Filing2 Dec 2025 - Sales and earnings fell year-over-year, but pharma and lubricant sales showed growth.UG
Q2 20258 Aug 2025 - Net income and sales rose on strong cosmetic demand; pharma sales to recover.UG
Q3 202413 Jun 2025 - Net sales and income soared, driven by cosmetic ingredient demand and pharma recovery.UG
Q2 202413 Jun 2025 - Sales and net income dropped sharply in Q1 2025, led by a 63% fall in cosmetic ingredient sales.UG
Q1 20256 Jun 2025 - Net income climbed 26% to $3.25M on robust sales growth in China.UG
Q4 20245 Jun 2025